Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, GPs can now prescribe Mounjaro (tirzepatide) on the NHS — but only for patients who meet strict eligibility criteria that are being phased in gradually. Right now, the NHS threshold sits at a BMI of 40 or above alongside four or more specific weight-related conditions. Many people searching for whether they can get Mounjaro from their GP simply do not meet those criteria yet, or find their practice has not yet opted into the new prescribing arrangements. Mounjaro is a prescription-only medicine; any legitimate route to it (NHS or private) requires a clinical assessment by a qualified prescriber.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is: it depends on the practice, and it depends on you. NICE approved tirzepatide for NHS use in December 2024 (guidance TA1026), but its rollout is deliberately staged. The first cohort (adults with a BMI of 40 or more plus at least four of five specified conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes)) became eligible from June 2025. A second cohort, covering BMI 35–39.9 with the same four-condition requirement, opened in June 2026. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, where the cut-offs are reduced by 2.5 kg/m².
Crucially, GP participation is voluntary. The 2026/27 GP contract allows practices to prescribe tirzepatide under QOF, but not every surgery has signed up. Even where a practice has joined, patients must also take part in a structured lifestyle support programme alongside the medicine. Meeting the BMI number on paper is necessary, it is not sufficient on its own.
If you are not sure where your practice stands, the most direct route is to ask. Some areas are moving quickly; others are still setting up the wraparound care pathways that NHS England requires. You can read more about what to expect when asking your GP about Mounjaro and what the appointment is likely to cover.
If you do qualify and your GP has opted in, an NHS prescription covers the medicine cost, but there are practical things worth knowing before you go in. Your GP will want your weight recorded, a review of current medications, and confirmation of your qualifying conditions. They are also likely to discuss the wraparound care requirements: NICE specifies that tirzepatide must be prescribed as part of a package that includes dietary advice and increased physical activity support.
There is also the matter of timing. Prescriptions are issued on a recurring cycle, and GP appointments are not always available the week you need them. If your review falls over a bank holiday, or the practice is short-staffed heading into August, you may find a gap between doses. That is worth planning for, not a reason to panic, but something to flag with your prescriber in advance. Our guide to taking a break from Mounjaro covers what a short gap actually means clinically.
Your GP will also want to review progress at six months. NICE guidance specifies that if weight loss is less than 5% after six months at the highest tolerated dose, continuing treatment should be reconsidered. That review is built into the NHS pathway.
Yes. The private route does not use NHS eligibility criteria, it uses the licensed criteria in the medicine's Summary of Product Characteristics. A prescriber at a GPhC-registered pharmacy can assess anyone who is an adult with a BMI of 30 or above, or 27 or above with at least one weight-related condition, provided there are no clinical contraindications. That is a meaningfully wider group than the NHS currently serves.
The clinical assessment still happens, it is a prescription-only medicine, and a prescriber makes the call, not an automated system. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. You can find out more about what the private consultation involves and what the prescriber is looking at. For broader context on accessing tirzepatide through different routes, the guide to getting Mounjaro in the UK covers both pathways side by side.
Cost is a real consideration. Private Mounjaro is priced per monthly pen, and since Eli Lilly adjusted UK list prices in September 2025, typical private prices across providers have ranged roughly £149–£375 per month depending on the dose and supplier. If cost is a factor, our honest guide to Mounjaro pricing in the UK explains what drives the variation and what those prices do and do not include. For a prescription medicine, the right questions are about clinical safety and supply-chain legitimacy, not which listing is cheapest.
The medicine is the same either way, genuine, licensed Mounjaro from the UK supply chain. What differs is the eligibility gate, the cost structure, and the speed of access. NHS prescriptions are free to qualifying patients (or subject to standard prescription charges depending on exemptions); private prescriptions carry the full medicine cost.
A private prescriber at a regulated online pharmacy can typically see your consultation the same day, confirm suitability, and dispatch within hours if you order before noon on a working day. An NHS appointment may take days to weeks to arrange, and stock allocation varies by area. Neither route is inherently better, the right one depends on your clinical profile, your circumstances, and whether you meet NHS thresholds. The NHS England page on weight management injections sets out the NHS pathway in full, including the wraparound-care requirements.
If you want to understand the broader picture of what tirzepatide is and how it works before deciding which route makes sense, the tirzepatide overview and the Mounjaro information page are good starting points. And if you are ready to see whether you qualify privately, you can check your eligibility with our prescribers, the consultation is free, and there is no obligation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.